Press Room

News / Apr 12, 2021

Guy Villax wins EY Award “Entrepreneur of the Year”

EY Entrepreneur Of The Year is the world's most prestigious business award for entrepreneurs

Guy Villax Wins Entreperneur of the Year Award | Hovione

Guy Villax won the EY award "Entrepreneur of the Year" in Portugal and he will represent Portugal at the EY World "Entrepreneur of the Year", next June.

Upon receiving the award, Guy Villax stated that this is an important distinction for Hovione, above all it recognizes the team that built this company over the last 25 years, and he thanked and congratulated all Hovione Team Members for the success. Guy Villax also said that we are a company with 60+ years, with strong values, with innovation at its core, but to endure into the future it needs to be able to constantly re-invent itself: “A company that does not move forward, dies. You have to constantly look for opportunities, look for ways to stay ahead of the competition, and innovation is central to success”.
 
The EY Award "Entrepreneur Of The Year" was created in the USA in 1986 to recognize and encourage Entrepreneurs that are marked by creativity that invest themselves in a corporate project with vision and achieve success. In Portugal, the EY “Entrepreneur Of The Year” is in its 8th edition.

 

Votes are open for the election of EY World Entrepreneur Of The Year™ 2021:

Cast your vote here

 

 

 

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026